ABSTRACT

Rhabdomyolysis is a condition of muscle cell death, resulting in acute to chronic kidney injury. Statins are known to be more safe, tolerated and the most effective drugs for treating hypercholesterolemia [1]. Rhabdomyolysis is a severe and rare adverse effect of statins, potentially leading to acute renal failure, promulgative intravascular coagulation, and gradually to death. According to the FDA, the mortality rate of Rhabdomyolysis is 0.15 per 1 million statin users [2]. Statins work by inhibiting the conversion of HMGCoA enzyme to Mevalonate by HMGCoA reductase. The exact mechanism of statin-induced Rhabdomyolysis is not known, but the occurrences are known to increase with the dose or their concentrations. The most common reasons for the myopathies associated with statin use are: cholesterol deficiency leading to renal membrane abnormalities, co-enzymes Q10 deficiency leading to abnormal mitochondrial respiratory function, or prenylated protein abnormalities leading to electrolytic imbalances [3]. The clinical spectrum of statin-induced myotoxicity includes a group of signs and symptoms, which ranges from asymptomatic elevations in serum Creatinine Phosphokinase (CPK) to more rare and severe myopathies and rarely, fatal Rhabdomyolysis [4]. This case describes a case on Rosuvastatin-induced Rhabdomyolysis with a fatal outcome in a patient receiving concurrent Everolimus and Statins for the past few years. Keywords: HMG-CoA, CK, Allograft, MVA, CPK, CMV
Publication date: 01/05/2025

https://ijbpas.com/pdf/2025/May/MS_IJBPAS_2025_8964.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.5.8964